<DOC>
	<DOCNO>NCT00003596</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine radiation therapy chemotherapy may kill tumor cell . It yet know whether fluorouracil mitomycin plus radiation therapy effective fluorouracil cisplatin plus radiation therapy anal cancer . PURPOSE : This randomized phase III trial study fluorouracil mitomycin plus radiation therapy see well work compare fluorouracil cisplatin plus radiation therapy treat patient stage II stage III anal cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Stage II Stage III Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare initial total local distant failure rate patient anal canal cancer treat either fluorouracil ( 5-FU ) plus mitomycin concurrently radiotherapy 5-FU plus cisplatin follow 5-FU plus cisplatin concurrently radiotherapy . - Identify differences local control colostomy rate 2 year patient treat regimen . - Determine difference colostomy free , disease free , overall survival patient treat regimen . - Compare toxic effect regimens patient . - Evaluate prognostic effect tumor marker P53 overexpression , human papilloma virus status , enzyme HAP1 patient treat regimen . OUTLINE : This randomize study . Patients stratify accord gender , nodal status ( positive v negative ) , primary tumor size ( great 2 cm 5 cm v great 5 cm ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fluorouracil ( 5-FU ) IV continuously 96 hour begin day 1 29 mitomycin IV day 1 29 concurrent radiotherapy . - Arm II : Patients receive induction chemotherapy comprise 5-FU IV continuously 96 hour begin day 1 , 29 , 57 , 85 cisplatin IV 1 hour day 1 , 29 , 57 , 85 . Beginning day 57 , patient receive concurrent radiotherapy . In arm , radiotherapy administer daily , 5 day week , 5-6.5 week . Patients T3 , T4 , N+ lesion T2 lesion residual disease receive additional radiotherapy reduce field . Patients follow every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 650 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary squamous , basaloid , cloacogenic carcinoma anal canal , carcinoma situ T24 , Any N , M0 ( stage II III ) No local regional recurrence local excision abdominal peritoneal resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Absolute neutrophil count least 1,800/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.4 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 80 mL/min Cardiovascular : No uncompensated heart disease No uncontrolled high blood pressure Other : No AIDS No active systemic infection No uncontrolled diabetes No prior malignancy within past 5 year except nonmelanoma skin cancer No mental condition would preclude study participation Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior epoetin alfa allow lieu blood transfusion Chemotherapy : At least 5 year since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 5 year since prior radiotherapy Surgery : No prior surgery anal canal except biopsy study site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage III anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>cloacogenic carcinoma anus</keyword>
	<keyword>basaloid carcinoma anus</keyword>
</DOC>